FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to experimental ophthalmology, and can be applied for suppression of positive regulation of short form of c-Maf transcription factor in processed with steroids or transforming growth factor β2 (TGF β2) cells of trabecular net. For this purpose introduced is antagonist c-Maf, also possessing inhibiting activity with respect to cyclin-dependent kinase cdk2, for instance purvalanol A.
EFFECT: invention explains mechanism and possible new approach to treatment of primary open-angle and steroid glaucoma.
4 cl, 1 tbl, 7 ex, 3 dwg
Authors
Dates
2009-10-20—Published
2004-12-21—Filed